CAJ | 학술논문

目的：探讨重组人血管内皮抑制剂联合化疗治疗晚期消化道肿瘤的临床疗效。方法：选取90例晚期消化道肿瘤患者为研究对象，分成2组，对照组44例，予常规化疗治疗，观察组46例，加用重组人血管内皮抑制剂治疗，观察治疗后疗效。结果：对照组缓解率36．36％、总有效率70．45％；观察组缓解率67．39％、总有效率89．13％，两组比较差异有统计学意义（P ＜0．05）；生活质量，对照组改善率15．91％、总有效率56．82％；观察组改善率41．30％、总有效率89．13％，两组比较差异有统计学意义（P ＜0．05）；生存时间，对照组0～6个月50．00％、＞6～12个月45．45％、＞12个月4．55％；观察组0～6个月17．39％、＞6～12个月65．22％、＞12个月17．39％，两组比较差异有统计学意义（P ＜0．05）；两组在白细胞下降、血小板下降、恶心呕吐、腹泻、周围神经毒性、心律失常、肝肾功能损害发生率上比较差异有统计学意义（P 均＜0．05）。结论：重组人血管内皮抑制剂联合化疗治疗晚期消化道肿瘤临床效果显著。
목적：탐토중조인혈관내피억제제연합화료치료만기소화도종류적림상료효。방법：선취90례만기소화도종류환자위연구대상，분성2조，대조조44례，여상규화료치료，관찰조46례，가용중조인혈관내피억제제치료，관찰치료후료효。결과：대조조완해솔36．36％、총유효솔70．45％；관찰조완해솔67．39％、총유효솔89．13％，량조비교차이유통계학의의（P ＜0．05）；생활질량，대조조개선솔15．91％、총유효솔56．82％；관찰조개선솔41．30％、총유효솔89．13％，량조비교차이유통계학의의（P ＜0．05）；생존시간，대조조0～6개월50．00％、＞6～12개월45．45％、＞12개월4．55％；관찰조0～6개월17．39％、＞6～12개월65．22％、＞12개월17．39％，량조비교차이유통계학의의（P ＜0．05）；량조재백세포하강、혈소판하강、악심구토、복사、주위신경독성、심률실상、간신공능손해발생솔상비교차이유통계학의의（P 균＜0．05）。결론：중조인혈관내피억제제연합화료치료만기소화도종류림상효과현저。
Objective:To study the effect of recombinant human vascular endothelial inhibitor combined with chemotherapy in patients with advanced gastrointestinal cancer.Methods:All 90 patients with advanced gastrointesti-nal cancer were divided into two groups,44 cases in the control group,received conventional chemotherapy treatment, 46 cases in the observation group,plus recombinant human vascular endothelial inhibitor treatment.Results:The effect of the control group response rate was 36.36%,the total efficiency 70.45%;67.39% response rate in the observation group,the total efficiency 89.13%,the difference was statistically significant(P <0.05).The quality of life of control group improved rate was 15.91%,the total efficiency 56.82%;improvement rate of 41.30% in the observation group,the total efficiency 89.13%,the difference was statistically significant (P <0.05).The survival time of 0 ~6 months in the control group was 50.00%,>6 ~12 months,45.45%,>12 months,4.55%.In observation group was 17.39% 0 ~6 months,>6 ~12 months,65.22%,17.39% for >12 months,the difference was statistically signifi-cant (P <0.05).Leukopenia,thrombocytopenia,nausea,vomiting,diarrhea,peripheral neurotoxicity,arrhythmia,liver and kidney dysfunction the difference was statistically significant (P <0.05).Conclusion:Recombinant human vas-cular endothelial inhibitor combined with chemotherapy in patients with advanced gastrointestinal cancer effect is re-markable.